ImmunoGen signs ADC deal with ImmunoBiochem
26 Jul 2023
License out/inImmunotherapyDrug ApprovalADCAccelerated Approval
Massachusetts-based ImmunoGen and Toronto-based ImmunoBiochem have inked a multi-target license and option agreement to advance novel, first-in-class ADCs.
The collaboration will combine ImmunoGen’s proprietary linker and payload technologies with ImmunoBiochem’s antibodies directed against specific targets.
ImmunoBiochem has developed novel ADCs and immunostimulatory antibody-drug conjugates (ISACs) based on novel cancer secretome target biology with efficacy in intractable solid tumors, including triple-negative breast cancer and pancreatic cancer.
ImmunoGen holds the most recent FDA approval in the ADC space with Elahere, which was granted accelerated approval last November for FRα-positive ovarian, fallopian tube or primary peritoneal cancerFRα-positive ovarian, fallopian tube or primary peritoneal cancer. The drugmaker recently announced additional phase 3 data that supports its mission to make Elahere the new standard of care for patients with FRα-positive platinum-resistant ovarian cancerFRα-positive platinum-resistant ovarian cancer.
Big ticket deals in the ADC space are on the rise, with the most notable being Pfizer's $43 billion acquisition of Seagen. On the collaboration front, Eisai and BlissBio recently announced a clinical trial collaboration agreement worth up to $2 billion. While the financial details of the ImmunoGen-ImmunoBiochem deal were not disclosed, ImmunoGen will pay ImmunoBiochem an upfront fee in exchange for an exclusive license to existing antibodies directed against a specific undisclosed target. ImmunoBiochem will be eligible to receive milestone payments and royalties.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.